# DNTH (Dianthus Therapeutics, Inc.) - SEC EDGAR Financial Statements

> Dianthus Therapeutics, Inc. reported $2.04M in revenue and a net loss of $202.1M for the fiscal year ended December 31, 2025 (down 67.3% year over year), with a -11592.7% operating margin.

- Canonical: https://convexityos.com/fundamentals/DNTH
- Markdown: https://convexityos.com/fundamentals/DNTH.md
- SEC CIK: 0001690585
- Reporting currency: USD
- Latest filing period: September 30, 2026
- Last synced: Nov 20, 2026, 05:16 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001690585&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | FY 2025 | $2.04M | -67.3% YoY |
| Operating Income | FY 2025 | -$236.0M | -11592.7% margin |
| Net Income | FY 2025 | -$202.1M | -9927.5% net margin |
| Diluted EPS | FY 2025 | -$3.52 | Split-adjusted |
| Free Cash Flow | FY 2025 | -- | Operating CF less CapEx |
| Cash & ST Investments | Sep 30, 2026 | $837.8M | Total debt: $1.21M |

## Income Statement

### Income Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Revenue** | $2.04M | $6.24M | $2.83M | -- | -- | -- | $0 | $0 | $0 | $0 |
| Research & Development | $145.6M | $83.11M | $32.84M | $29.38M | $46.77M | $50.62M | $59.21M | $41.34M | $27.90M | $5.78M |
| Total Operating Expenses | $180.0M | $108.1M | $51.00M | $36.12M | $74.69M | $78.70M | $82.97M | $59.96M | $35.73M | $9.27M |
| **Operating Income** | -$177.9M | -$101.9M | -$48.17M | -$29.70M | -$74.69M | -$78.70M | -$82.97M | -$59.96M | -$35.73M | -$9.27M |
| **EBITDA** | -$177.8M | -$101.8M | -$48.11M | -$27.78M | -$72.67M | -$76.72M | -$81.13M | -$59.09M | -$35.35M | -$9.26M |
| Interest Income | $9.96M | $11.35M | $3.34M | $1.15M | -- | -- | -- | -- | -- | -- |
| Interest Expense | -- | -- | -- | -- | -- | -- | -- | -- | -- | $163K |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| **Net Income** | -$162.3M | -$84.97M | -$43.55M | -$28.48M | -$71.14M | -$74.94M | -$76.77M | -$57.52M | -$35.49M | -$9.43M |
| Basic EPS | -$4.20 | -$2.55 | -$8.45 | -$32.57 | -$1.29 | -$1.71 | -$2.07 | -$3.13 | -$19.12 | -$65.15 |
| **Diluted EPS** | -$4.20 | -$2.55 | -$8.45 | -$32.57 | -$1.29 | -$1.71 | -$2.07 | -$3.13 | -$19.12 | -$65.15 |
| Basic Shares Outstanding | 38.6M | 33.3M | 5.2M | 874.2K | 54.9M | 43.9M | 37.0M | 18.4M | 1.9M | 149.4K |
| Diluted Shares Outstanding | 38.6M | 33.3M | 5.2M | 874.2K | 54.9M | 43.9M | 37.0M | 18.4M | 1.9M | 149.4K |

### Income Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Revenue** | -- | -- | -- | $284K | $396K | $193K | $1.16M | $1.33M |
| Research & Development | $45.60M | $48.69M | $34.53M | $59.90M | $32.49M | $26.25M | $27.00M | $26.41M |
| Total Operating Expenses | $59.68M | $62.24M | $47.00M | $69.83M | $40.68M | $35.12M | $34.34M | $33.24M |
| **Operating Income** | -$58.47M | -$61.48M | -$46.53M | -$69.54M | -$40.29M | -$34.93M | -$33.18M | -$31.92M |
| **EBITDA** | -$58.44M | -$61.45M | -$46.50M | -$69.51M | -$40.26M | -$34.90M | -$33.15M | -$31.89M |
| Interest Income | $11.26M | $5.89M | $5.05M | $4.41M | $1.35M | $2.31M | $1.89M | $1.25M |
| **Net Income** | -$46.64M | -$50.22M | -$40.83M | -$64.43M | -$36.77M | -$31.63M | -$29.51M | -$28.44M |
| Basic EPS | -$0.81 | -$0.90 | -$0.85 | -- | -$0.97 | -$0.88 | -$0.82 | -- |
| **Diluted EPS** | -$0.81 | -$0.90 | -$0.85 | -- | -$0.97 | -$0.88 | -$0.82 | -- |
| Basic Shares Outstanding | 57.3M | 56.0M | 48.0M | -- | 37.8M | 35.8M | 35.8M | -- |
| Diluted Shares Outstanding | 57.3M | 56.0M | 48.0M | -- | 37.8M | 35.8M | 35.8M | -- |

## Balance Sheet

### Balance Sheet (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $51.09M | $22.79M | $132.3M | $15.37M | $131.7M | $58.15M | $65.07M | $58.34M | $51.40M |
| Short-Term Investments | $353.2M | $252.4M | $41.39M | $60.12M | $45.28M | $90.68M | $80.66M | $84.22M | -- |
| **Cash & Short-Term Investments** | $50.25M | $21.95M | $131.2M | $75.49M | $176.9M | $148.8M | $145.7M | $142.6M | $51.40M |
| Accounts Receivable, Net | $52K | $0 | $294K | $4.70M | -- | -- | -- | -- | -- |
| Other Current Assets | $86K | $355K | $0 | -- | -- | -- | -- | -- | -- |
| **Total Current Assets** | $409.4M | $280.9M | $177.5M | $82.03M | $180.7M | $151.5M | $149.8M | $145.3M | $52.50M |
| Property, Plant & Equipment, Net | $296K | $194K | $185K | $142K | $7.46M | $8.31M | $9.89M | $10.21M | $1.96M |
| Long-Term Investments | $110.1M | $81.73M | $0 | -- | -- | -- | -- | -- | -- |
| Other Non-Current Assets | -- | -- | -- | -- | -- | -- | -- | -- | $4.0K |
| **Total Non-Current Assets** | $121.5M | $93.10M | $1.95M | $1.08M | $9.24M | $10.09M | $11.67M | $11.99M | $1.96M |
| **Total Assets** | $530.9M | $374.0M | $179.4M | $83.11M | $189.9M | $161.6M | $161.5M | $157.3M | $54.46M |
| Accounts Payable | $9.72M | $4.58M | $2.61M | $1.17M | $3.04M | $3.76M | $2.81M | $3.49M | $167K |
| Deferred Revenue (Current) | $1.19M | $479K | $0 | $100K | -- | -- | -- | -- | -- |
| **Total Current Liabilities** | $30.73M | $18.45M | $9.63M | $8.22M | $10.86M | $11.43M | $14.12M | $10.42M | $4.14M |
| Deferred Revenue (Non-Current) | $5.77M | $1.91M | $0 | $791K | -- | -- | -- | -- | -- |
| **Total Non-Current Liabilities** | $6.79M | $3.08M | $904K | $1.23M | $6.40M | $6.28M | $6.21M | $1.25M | $0 |
| **Total Liabilities** | $37.52M | $21.53M | $10.54M | $9.45M | $17.26M | $17.71M | $20.32M | $11.66M | $4.14M |
| **Total Debt (incl. Leases)** | $1.39M | $1.49M | $585K | $29.96M | -- | -- | -- | -- | -- |
| Common Stock | $43K | $31K | $15K | $0 | $59K | $49K | $39K | $33K | $2.0K |
| Retained Earnings | -$336.7M | -$174.4M | -$89.42M | -$45.87M | -$325.6M | -$254.4M | -$179.5M | -$102.7M | -$45.21M |
| Accumulated Other Comp. Income | $489K | $106K | $47K | -$161K | -$30K | -$23K | $8.0K | -$8.0K | -- |
| **Total Stockholders' Equity** | $493.4M | $352.5M | $168.9M | -$44.37M | -$17.25M | $143.9M | $141.2M | $145.6M | -$42.12M |
| Total Equity | $493.4M | $352.5M | $168.9M | -$44.37M | -$17.25M | $143.9M | $141.2M | $145.6M | -$42.12M |

### Balance Sheet (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $55.69M | $110.5M | $627.7M | $51.09M | $55.98M | $13.24M | $10.12M | $22.79M |
| Short-Term Investments | $782.1M | $776.3M | $483.6M | $353.2M | $346.6M | $244.2M | $253.1M | $252.4M |
| **Cash & Short-Term Investments** | $54.08M | $107.6M | $617.1M | $50.25M | $54.99M | $11.95M | $9.25M | $21.95M |
| Accounts Receivable, Net | $582K | $106K | $1.23M | $52K | $5.00M | $39K | $1.00M | $0 |
| Other Current Assets | $169K | $184K | $83K | $86K | $73K | $111K | $392K | $355K |
| **Total Current Assets** | $856.0M | $897.5M | $1.12B | $409.4M | $413.8M | $263.6M | $271.0M | $280.9M |
| Property, Plant & Equipment, Net | $749K | $418K | $274K | $296K | $185K | $207K | $191K | $194K |
| Long-Term Investments | $406.0M | $303.6M | $113.9M | $110.1M | $152.9M | $51.70M | $68.31M | $81.73M |
| **Total Non-Current Assets** | $420.2M | $315.7M | $127.0M | $121.5M | $163.6M | $62.47M | $77.58M | $93.10M |
| **Total Assets** | $1.28B | $1.21B | $1.25B | $530.9M | $577.4M | $326.1M | $348.6M | $374.0M |
| Accounts Payable | $5.50M | $6.39M | $5.27M | $9.72M | $6.71M | $5.40M | $8.27M | $4.58M |
| Deferred Revenue (Current) | $1.59M | $1.52M | $1.49M | $1.19M | $954K | $479K | $479K | $479K |
| **Total Current Liabilities** | $28.52M | $34.39M | $38.28M | $30.73M | $23.86M | $20.09M | $16.95M | $18.45M |
| Deferred Revenue (Non-Current) | $5.45M | $5.94M | $6.32M | $5.77M | $6.07M | $1.78M | $1.85M | $1.91M |
| **Total Non-Current Liabilities** | $6.31M | $6.86M | $7.29M | $6.79M | $7.14M | $2.90M | $3.02M | $3.08M |
| **Total Liabilities** | $34.82M | $41.25M | $45.57M | $37.52M | $30.99M | $23.00M | $19.97M | $21.53M |
| **Total Debt (incl. Leases)** | $1.21M | $1.29M | $1.36M | $1.39M | $1.28M | $1.33M | $1.40M | $1.49M |
| Common Stock | $56K | $55K | $54K | $43K | $43K | $32K | $32K | $31K |
| Retained Earnings | -$474.4M | -$427.8M | -$377.6M | -$336.7M | -$272.3M | -$235.5M | -$203.9M | -$174.4M |
| Accumulated Other Comp. Income | -$6.28M | -$2.13M | -$575K | $489K | $163K | $98K | $270K | $106K |
| **Total Stockholders' Equity** | $1.24B | $1.17B | $1.20B | $493.4M | $546.5M | $303.1M | $328.6M | $352.5M |
| Total Equity | $1.24B | $1.17B | $1.20B | $493.4M | $546.5M | $303.1M | $328.6M | $352.5M |

## Cash Flow Statement

### Cash Flow Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$162.3M | -$84.97M | -$43.55M | -$28.48M | -$71.14M | -$74.94M | -$76.77M | -$57.52M | -$35.49M | -$9.43M |
| Depreciation & Amortization | $111K | $96K | $67K | $1.93M | $2.02M | $1.98M | $1.84M | $875K | $376K | $6.0K |
| Stock-Based Compensation | $22.79M | $12.89M | $2.90M | $1.52M | $10.31M | $9.94M | $10.00M | $10.70M | $2.26M | $662K |
| Change in Receivables | -$52K | $0 | -- | -- | -- | -- | -- | -- | -- | -- |
| Change in Payables | -- | -- | -- | -$801K | -$720K | $948K | $145K | $2.50M | -$1.12M | $1.01M |
| **Operating Cash Flow** | -$129.1M | -$78.18M | -$36.86M | -$29.07M | -$59.53M | -$64.02M | -$57.10M | -$41.89M | -$22.26M | -$6.53M |
| Capital Expenditure | -- | -- | -- | -$314K | -$1.26M | -$400K | -$3.06M | -$7.67M | -$2.20M | -$139K |
| **Free Cash Flow** | -- | -- | -- | -$29.38M | -$60.80M | -$64.42M | -$60.16M | -$49.56M | -$24.46M | -$6.67M |
| Purchases of Investments | -$435.0M | -$413.7M | -$57.42M | -$69.50M | -$45.31M | -$95.73M | -$144.4M | -$84.04M | -- | -- |
| **Investing Cash Flow** | -$122.8M | -$286.8M | $20.25M | -$59.82M | $43.43M | -$10.63M | $1.53M | -$91.70M | -$2.20M | -$139K |
| Common Stock Issued | $317K | $0 | $0 | $2.90M | $0 | $64.86M | $60.87M | $93.00M | -- | -- |
| **Financing Cash Flow** | $280.1M | $255.6M | $133.6M | $96.68M | $89.60M | $67.74M | $62.30M | $142.1M | $71.49M | $10.71M |
| **Net Change in Cash** | $28.23M | -$109.4M | $117.0M | $7.79M | $73.50M | -$6.92M | $6.73M | $8.56M | $47.02M | $4.04M |

### Cash Flow Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$46.64M | -$50.22M | -$40.83M | -$64.43M | -$36.77M | -$31.63M | -$29.51M | -$28.44M |
| Depreciation & Amortization | $37K | $37K | $32K | $27K | $27K | $30K | $27K | $26K |
| Stock-Based Compensation | $12.72M | $11.90M | $10.60M | $5.98M | $5.79M | $5.71M | $5.32M | $3.92M |
| Change in Receivables | -$476K | $1.12M | -$1.18M | $4.95M | -$4.96M | $961K | -$1.00M | $0 |
| **Operating Cash Flow** | -$50.33M | -$48.98M | -$28.86M | -$46.98M | -$30.55M | -$23.89M | -$27.63M | -$27.44M |
| Purchases of Investments | -$323.1M | -$565.8M | -$238.6M | -$54.73M | -$279.8M | -$33.11M | -$67.32M | -$108.1M |
| **Investing Cash Flow** | -$111.9M | -$478.5M | -$134.0M | $37.20M | -$201.3M | $26.45M | $14.79M | -$23.11M |
| Common Stock Issued | $244K | $0 | $120K | $1.0K | $187K | $0 | $129K | $0 |
| **Financing Cash Flow** | $107.5M | $10.38M | $739.4M | $4.88M | $274.5M | $568K | $161K | $39.68M |
| **Net Change in Cash** | -$54.73M | -$517.1M | $576.6M | -$4.90M | $42.68M | $3.12M | -$12.68M | -$10.88M |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Operating Margin** | -8739.3% | -1633.7% | -1704.7% | -- | -- | -- | -- | -- | -- | -- |
| **Net Profit Margin** | -7973.3% | -1362.8% | -1541.2% | -- | -- | -- | -- | -- | -- | -- |
| Return on Equity (ROE) | -32.9% | -24.1% | -25.8% | -- | -- | -52.1% | -54.4% | -39.5% | -- | -- |
| Return on Assets (ROA) | -30.6% | -22.7% | -24.3% | -34.3% | -37.5% | -46.4% | -47.5% | -36.6% | -65.2% | -- |
| Current Ratio | 13.32x | 15.22x | 18.42x | 9.97x | 16.63x | 13.26x | 10.62x | 13.95x | 12.68x | -- |
| Quick Ratio | 1.64x | 1.19x | 13.65x | 9.75x | 16.29x | 13.02x | 10.32x | 13.68x | 12.41x | -- |
| Debt to Equity | 0.00x | 0.00x | 0.00x | -- | -- | -- | -- | -- | -- | -- |
| **Revenue Growth (YoY)** | -67.3% | +120.6% | -- | -- | -- | -- | -- | -- | -- | -- |

### Profitability Ratios & YoY Growth (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Operating Margin** | -- | -- | -- | -8739.3% | -4558.4% | -2676.6% | -1796.4% | -1633.7% |
| **Net Profit Margin** | -- | -- | -- | -7973.3% | -4104.8% | -2364.1% | -1544.0% | -1362.8% |
| Return on Equity (ROE) | -16.3% | -16.4% | -14.5% | -32.9% | -23.1% | -37.9% | -30.7% | -24.1% |
| Return on Assets (ROA) | -15.8% | -15.8% | -13.9% | -30.6% | -21.9% | -35.2% | -28.9% | -22.7% |
| Current Ratio | 30.02x | 26.10x | 29.25x | 13.32x | 17.35x | 13.12x | 15.99x | 15.22x |
| Quick Ratio | 1.92x | 3.13x | 16.15x | 1.64x | 2.51x | 0.60x | 0.60x | 1.19x |
| Debt to Equity | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x |
| **Revenue Growth (YoY)** | -- | -- | -- | -78.6% | -81.8% | -89.6% | +33.1% | -- |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
